Scinai Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Scinai Immunotherapeutics has a total shareholder equity of $-2.7M and total debt of $18.6M, which brings its debt-to-equity ratio to -691%. Its total assets and total liabilities are $18.6M and $21.3M respectively.
Key information
-691.0%
Debt to equity ratio
US$18.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.36m |
| Equity | -US$2.69m |
| Total liabilities | US$21.27m |
| Total assets | US$18.58m |
Recent financial health updates
Recent updates
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10
Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Financial Position Analysis
Short Term Liabilities: SCNI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SCNI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SCNI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SCNI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SCNI has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SCNI is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.